NEWS

January 09, 2024

Adovate, Awarded $800,000 by Virginia Catalyst for Phase 2 Clinical Trial of ADO-5030

 ADO-5030 has the potential to transform the treatment of asthma. Charlottesville, VA – January 9, 2024 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing drug candidates targeting the adenosine receptors, today announced its receipt of a

Read More

Feburary 1st, 2024

Adovate Completes Key Obligations Related to Acquisition of Its Adenosine Drug Development Platform  

Security interests & anti-dilution encumbrances on assets settled. Charlottesville, VA – Feb 1, 2024 – Adovate, LLC (“Adovate” or “the Company”), a pharma firm focusing on adenosine receptor drugs for major diseases, updates acquisition of adenosine drug platform & assets

Read More